CoChat

Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment

Open access
Lê, Phu Quoc, Gulbis, Béatrice, Dedeken, Laurence, Dupont, Sophie, Vanderfaeillie, Anna, Heijmans, Catherine, Huybrechts, Sophie, Devalck, Christine, Efira, André, Dresse, Marie‐Françoise, Rozen, Laurence, Benghiat, Fleur Samantha, Ferster, Alina · 2015 · Pediatric Blood & Cancer
Cited by 164

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Objective: To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease‐modifying treatments (DMT). Method: The Registry created in 2008 included patients of eight centers. All available data in 2008 were retrospectively encoded in the database. After 2008 and until 2012, all data were recorded prospectively for already registered patients as well as newly diagnosed subjects. Data were registered from neonatal screening or from diagnosis (first contact) until last follow‐up or death. Data included diagnosis, demography, and outcome data. Results: We collected data from 469 patients over a 5,110 patient years (PY) follow‐up period. The global mortality rate was low (0.25/100 PY), although 13 patients died (2.8%) and was similar between children, adolescents (10–18 years), and young adults (P = 0.76). Out of the cohort, 185 patients received hydroxyurea at last follow‐up (median duration of treatment: 10.3 years), 90 underwent hematopoietic stem cell transplantation (HSCT), 24 were chronically transfused, and 170 had never had any DMT. Hydroxyurea showed significant benefit on patients outcome as reflected by a lower mortality rate compared to transplanted individuals or people without DMT (0.14, 0.36, and 0.38 per 100 PY, respectively) and by higher Kaplan–Meier estimates of 15 year survival (99.4%) compared to HSCT (93.8%; P = 0.01) or no DMT groups (95.4%; P = 0.04). Conclusion: SCD mortality in Belgium is low with no increase observed in young adults. Patients treated with hydroxyurea demonstrate a significant benefit in survival when compared to those without DMT or transplanted. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.25608

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 164

Metadata

Authors
Lê, P. Q., Gulbis, B., Dedeken, L., Dupont, S., Vanderfaeillie, A., Heijmans, C., Huybrechts, S., Devalck, C., Efira, A., Dresse, M., Rozen, L., Benghiat, F. S., & Ferster, A.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2015-07-14
Volume
62
Issue
11
Pages
1956-1961
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W1962573931
Cited by
164
References
11
FWCI
11.74
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment. https://app.cochat.ai/papers/10.1002/pbc.25608
The paper
Lê, P. Q., Gulbis, B., Dedeken, L., Dupont, S., Vanderfaeillie, A., Heijmans, C., Huybrechts, S., Devalck, C., Efira, A., Dresse, M., Rozen, L., Benghiat, F. S., & Ferster, A. (2015). Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.25608

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.